Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUMEN-1: Lutathera for recurrent meningioma
NL-OMON59933Phase 2Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Aug 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in meningioma comparing Lutathera with Local standard of care (2 arms). Primary endpoint: Progression-free survival. Started Aug 2026; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
meningioma
Beyond the preview
Go deeper on NL-OMON59933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59933.